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Summary
Against all odds, as a foreign body in a coronary artery 
was considered too thrombogenic, coronary artery 
stents have become a standard feature of percutaneous 
coronary intervention (PCI). After initial reluctance to 
employ coronary stents based on misinterpretation of 
thrombosis rates when stents were exclusively used for 
bail-out procedures, stent overuse took over quickly. 
Balloon angioplasty results indicated that only 25% of 
lesions can possibly benefit from a stent. A stent im-
planted in the remaining 75% of lesions is without any 
chance to help but carries some risk to harm. However, 
the risk of harm has become so small with ever improv-
ing stents that default stenting has become acceptable. 
Avid stent implanters argue that only 100% stenting 
assures that the 25% of lesions needing a stent indeed 
get a stent. Shortly after drug-eluting stents (DES) had 
been introduced, they were falsely accused of being 
dangerous on the ground of their higher propensity for 
stent thrombosis after the first year compared to bare 
metal stents (BMS). In fact, they had significantly 
fewer early stent thromboses during the first year irre-
spective of the extent of antiplatelet therapy. This 
advantage was admittedly progressively lost over the 
years. Subsequent generations of DES enhanced this 
early reduction of stent thrombosis but no longer 
showed that late catch-up phenomenon. These facts are 
ignored or misinterpreted to the present date by most 
physicians and all guidelines and textbooks. It was al-
ways preferable to implant a DES rather than a BMS 
when there was concern about stent thrombosis, be it 
because of need of early surgery or another impossibil-
ity to maintain double antiplatelet therapy. The respec-
tive advantage of current generation DES is over-
whelming so that using a BMS is close to unethical. 
The most recent misconception, i.e., the need to have an 
absorbable stent, is also principally based on the myth 
of DES to be overly thrombogenic. The current absorb-
able stents disappear at best after a few years when 
the risk of a late stent thrombosis 
with a modern DES is virtually 
nil. Other reasons for absorbable 
stents, such as restitution of nor-
mal histology and vasomotion, easy 
accessibility of the stented segment 
for later bypass graft insertion, less 
stent malapposition to the vessel wall, and reduced 
need for antiplatelet therapy are either wrong or clini-
cally trivial.
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Introduction
We do not even know what the word stent means, no 
wonder we know even less how to best deal with this 
thing. Charles Stent, an English dentist who developed 
a bracing mold for oral surgery in 1856, is most likely 
the name’s father [1]. He now not only features a com-
mon noun but also a verb named after him. Metallic 
implants (e.g., copper coils) had been used by early in-
vasive cardiologists to experimentally thrombose coro-
nary arteries. Using such an implant to prevent throm-
botic closure appeared paradoxical. Andreas Gruentzig, 
the father of percutaneous coronary intervention (PCI), 
toyed with the idea of tacking the unavoidable intimal 
flap after peripheral or coronary balloon angioplasty to 
the wall with a metallic scaffold but gave it only a mod-
est chance of success. It was not going to be his to wit-
ness the first human coronary stent implantation, let 
alone to perform it himself.
History of coronary stenting
Apart from Gruentzig’s group, several other teams 
worked on the development of a scaffold to tame the 
ominous coronary dissection, the fundamental mecha-
nism of balloon angioplasty, by preventing it from ob-
structing blood flow and causing a thrombus. Cesare 
Gianturco and Julio Palmas in the United States and 
Hans Wallsten in Switzerland were the minds behind 
the three original coronary stent designs. Hans Wall-
sten won the race when Jacques Puel implanted the 
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(risk of 7% without stent) nor clinically relevant reste-
nosis (risk of about 25% with some overlap). Subtract 
from the resulting 30% about 5% of lesions that will 
have a problem in spite of a stent. Hence, the ideal 
interventional cardiologist should be able to anticipate 
the 25% of lesions needing and benefiting from a stent 
and not implant a stent in the remaining 75%. This was 
the exact conclusion of a paper comparing restenosis 
reduction of randomised trials between plain old bal-
loon angioplasty (POBA) and coronary stenting [5]. 
Moreover, a paper looking at the late outcomes in the 
first such randomised trial, the Belgian-Netherlands-
Stent (BeNeStent) study, even made out a prognostic 
disadvantage of placing stents into every lesion [6]. 
Such a strategy doubled mortality from 3% to 6% and 
infarction rate from 4% to 8%. These papers were cava-
lierly ignored because they appeared in an era of early 
stent frenzy when the optical appeal of a stented com-
pared to a fuzzy nonstented POBA lesion had already 
conquered virtually every interventional cardiologist’s 
mind. So the community of interventional cardiologists 
misguidedly jeopardised patient outcome while in-
creasing the cost of PCI for the sake of angiographically 
impeccable results and for their deficient capability to 
predict which lesion should and which lesion should 
not get a stent. This behaviour was ethically question-
able until the stents got so much better and safer that 
putting one in a lesion that does not need it can no 
longer be called a threat.
Drug-eluting stents and the restenosis bubble
The so-called drug-eluting stents (DES) were a wel-
come and palpable improvement of the original bare 
metal stents (BMS). Yet, to make the DES advantage 
look better than it really was and to justify their prices 
first of his coronary stents (named Wallstent, what 
else?) on 29 March 1986 in Toulouse, France [2], in an 
elective stent implantation to treat restenosis after 
balloon angioplasty. The principal idea behind the 
stent development, however, had been to use it as a 
bail-out device in case of a threatened or accomplished 
obstructive dissection after balloon angioplasty. Ulrich 
Sigwart in Lausanne was the first to use Wallstents to 
that end in the months following Puel’s ground-break-
ing elective case. In the subsequent almost 30 years to 
the present day, stents have become a sine qua non of 
PCI and they have been refined based on the experi-
ence gathered with millions of patients. On top of im-
proved profiles and flexibility for easy introduction, 
thrombogenicity has been drastically reduced and the 
feature of an antiproliferative drug, eluted during the 
first weeks to months, also curbed restenosis to a per-
fectly acceptable level. 
Clinical results of coronary stents and their 
many misinterpretations
The stent held its promise when comparing the acute 
results of PCI before [3] and after [4] the advent of coro-
nary stents. Mortality was reduced from 5% to 1%, 
myo cardial infarction from 40% to 4%, and need for 
emergency coronary artery bypass grafting from 40% 
to 1%. Somewhat as a bonus, stenting also reduced 
restenosis (re-narrowing of the enlarged lumen by elas-
tic recoil and overzealous endothelial proliferation), 
particularly in smaller vessels and short stent seg-
ments. Preventing recoil is the mechanism for that. Ac-
counting for these facts, it could be deduced that about 
25% of lesions should be stented. The mathematics are 
that 70% of lesions will neither suffer abrupt closure 
Figure 1 
Restenosis rate of the Bx-Velocity bare metal 
stent and its drug-eluting successor, the 
Cypher stent, looking at studies performed 
in the era before (pre DES) and after 
introduction of the Cypher stent. 
BMS = bare metal stents; DES = drug-eluting 
stents; E-SIRIUS [11] = Sirolimus-eluting 
stents for treatment of patients with long 
atherosclerotic lesions in small coronary 
arteries; Pts = patients; RAVEL [9] = Ran-
domised study with the sirolimus-coated 
Bx-Velocity balloon- expandable stent in the 
treatment of patients with de novo native 
coronary artery lesions; SIRIUS [10] = 
Sirolimus-eluting balloon-expandable stent in 
the treatment of patients with de novo native 
coronary artery lesions; VELVET [8] = Direct 
stenting with the Bx-Velocity balloon-expand-
able stent mounted on the rapid exchange 
delivery  system versus predilatation in a 
European randomised trial; VENUS [7] = 
Bx-Velocity stenting native coronary lesions in 
the United States.
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that amounted to more than double of those of BMS, 
opinion leaders applied what is generally used in such 
situations. The restenosis rate of BMS, shown to be 
 between 10% and 30% in many scientific papers com-
paring BMS to POBA and causing a need for reinter-
vention in about 5% to 10% [5], was boosted up to make 
the already remarkable single digit restenosis rate of 
early generation DES look really extraordinary. DES 
restenosis rate was presented on the background of 
“revised” BMS restenosis rates of 20% to 40%, figures 
that had appeared nowhere before the advent of DES. 
Figure 1 [7–11] depicts that graphically, pertaining to 
the market-leading BMS at the time of DES introduc-
tion, the Bx-Velocity stent, which also was the platform 
of the first DES called Cypher.
Notwithstanding, the restenosis rate and the need 
for re-intervention were indeed reduced by DES com-
pared to BMS. Even more importantly, the difficult-to-
treat long and diffuse in-stent restenoses have virtu-
ally disappeared with DES.
Drug-eluting stents and the double-antiplatelet 
therapy myth
Initially, stenting was used almost exclusively in bail-
out situations. The ensuing stent thrombosis rate was 
around 20%. This was a remarkable success consider-
ing that before stents these situations had resulted in 
>50% of vessel thrombosis. However, when looking at a 
20% thrombosis rate in stented cases and comparing 
them to the thrombosis rate of elective POBA (about 
7%) or other devices being propagated in the 1980s 
such as directional atherectomy or rotablation (about 
10% each), the stent came in last for all the wrong rea-
sons. Stenting was therefore taken up quite reluctantly 
particularly in the United States of America [12]. The 
traditional drug treatment at that time was oral anti-
coagulation with a vitamin K antagonist (VKA). Dou-
ble antiplatelet therapy (DAPT) was introduced in par-
allel to the transition from bail-out to elective coronary 
stenting. The fact that the observed stent thrombosis 
rate rapidly dropped to less than 5% was erroneously 
attributed to the DAPT and perhaps the simulta-
neously recommended high-pressure balloon stent im-
plantation while it was basically the reflection of elec-
tive rather than bail-out stenting. 
Subsequently, VKA was banned to make way for 
DAPT as the new overemphasised post-stent medical 
treatment standard. Uncritically, the problem of stent 
thrombosis, particularly during the first months, was 
accepted as a price to pay for less in-hospital lesion 
Figure 2
Histological (courtesy Michael Joner, MD) and graphical depiction of clinically relevant stent features. The first generation drug-eluting stents, 
Cypher (sirolimus-eluting [S-ES]) and Taxus (paclitaxel-eluting [P-ES]), had an overly thin coating of the stent struts due to overdosing of the 
antiproliferative drug effecting an increased thrombosis potential due to late erosions or fissures of the thin coat. The Taxus stent in addition 
showed a nonhomogenous endothelial proliferation with some overproliferative areas causing restenosis (best depicted in the longitudinal section 
at the top). The current generation DES like Endeavor (zotarolimus-eluting [Z-ES]) and Xience (everolimus-eluting [E-ES]) engender a homogenous 
still thin but thick enough coat preventing both, restenosis and stent thrombosis. The bare metal stent (BMS) in  comparison at the right has a 
homogenous but overly thick coat unlikely to erode or fissure and cause thrombosis but engendering some degree of restenosis.
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Figure 3
Stent thrombosis with bare metal stents 
(BMS) [14] and drug-eluting stents (DES) 
[15] during the first three years. While 
the overall incidence is comparable, there 
are clearly more late and very late stent 
thromboses with DES than with BMS 
which was recognised and repeatedly 
highlighted. Equally apparent but ignored 
was the fact that there were fewer early 
stent thromboses with DES.
Figure 4
Prognostic outcome of patients treated 
with drug-eluting stents (DES, number 
of patients in parentheses) or bare metal 
stents (BMS) in a nationwide Danish 
registry with a 15-month follow-up. 
The significantly increased risk of stent 
thrombosis with DES during months 
12 to 15 was presented but not 
sufficiently declared as an isolated 
finding. As shown here in the overall 
context, it is of negligible importance and 
DES are superior on all other accounts.
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thrombosis and reduced restenosis, the two major 
banes of POBA that on the other hand knows no lesion 
thrombosis after hospital discharge. Stent thromboses 
after one year were rare because by then a thick neo-
intimal coat usually covered the entire BMS (fig. 2). 
When DES were announced for clinical use, we and 
others were warned to expect more late stent thrombo-
ses due to the thinner neointimal coverage of the 
stents, the targeted effect of the antiproliferative drug 
on DES [13]. This prophecy was fulfilled (fig. 3) [14, 15] 
and in 2006 the situation went out of control. Then the 
uncontested increased risk of stent thrombosis at 
around 1 year of follow-up was inappropriately high-
lighted in an isolated manner by several reports [16, 
17]. They failed to point out clearly enough that they 
focused on the time around 1 year and they did not 
acknowledge the respective advantage in favour of 
DES accrued over the first year. Figure 4 exemplifies 
the distorted presentation of the real but rather petty 
DES thrombosis problem [16].
Unfortunately this capped the uprise of DES use 
worldwide, quite to detriment of patients. It also led to 
the false general opinion that patients at a particular 
risk of stent thrombosis early on, like those needing 
major surgery soon after stenting and patients un-
likely to comply with DAPT, should get a BMS rather 
than a DES. While this was wrong already with first 
generation DES, it has become absurd with modern 
DES. For these, the lower early stent thrombosis risk 
compared to BMS is even more marked and there is no 
longer any catch-up in thrombosis after the first year. 
While BMS stent thrombosis rate at two years is 1.4%, 
it was 1.3% for first generation DES and is 0.6% for 
contemporary DES [18]. In a long-term follow-up study, 
even the first-generation sirolimus-eluting Cypher 
stent maintained a lower stent thrombosis rate than 
BMS even at 7 years in over 10 000 patients [19]. All 
this is independent of the presence or duration of 
DAPT. To the contrary, a study on the benefit of pro-
longed DAPT showed that DES are less benefiting from 
it than BMS [20]. Animal studies comparing the throm-
bosis rates of a large variety BMS and of DES proved a 
lower propensity for thrombosis of DES and underlined 
that this ran against common perception [21]. An ex-
planation for reduced early stent thrombosis of DES 
may be the polymer, the drug container coating the 
metal. It may be anti-thrombogenic while the stent is 
not yet covered by endothelium. Figure 2 plausibly ex-
plains the disparate risks of stent designs to produce 
restenosis or stent thrombosis.
Several papers examined the incidence of myocar-
dial infarction as a surrogate of stent thrombosis of 
BMS versus DES in patients undergoing surgery after 
stenting, which usually requires interruption of DAPT 
if not of all antiplatelet therapy. They again disproved 
the general opinion that BMS are safer and docu-
mented beyond reasonable doubt and once and for all 
that, indeed, DES are safer [22–25].
Conclusion
It is about time to acknowledge the abundant litera-
ture testifying to the fact that DES are superior to 
BMS on all accounts without any exception and to en-
joy the superb results with their modern versions. Cur-
rent DES feature unparalleled user-friendliness, need 
for re-intervention in the low single digits, and risk for 
stent thrombosis of about 1% in the first year and prac-
tically zero after that with little dependences on DAPT 
per se or on DAPT duration. This touches on perfection 
and the currently reprimandable attitude to stent 
every coronary lesion approached needs no longer be 
frowned upon. Hence, the saying that absorbable stents 
are the future of PCI and will always be is quite fitting 
as besting modern metal DES may likely prove impos-
sible.
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